Literature DB >> 19721439

Trial watch: BLYS-targeted antibody shows promise in Phase III SLE trial.

.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19721439     DOI: 10.1038/nrd2984

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  1 in total

1.  Systemic lupus erythematosus.

Authors:  James Wentworth; Clare Davies
Journal:  Nat Rev Drug Discov       Date:  2009-02       Impact factor: 84.694

  1 in total
  4 in total

1.  A rich pipeline that needs to be managed.

Authors:  Keith Bradbury
Journal:  Biotechnol Healthc       Date:  2009-10

Review 2.  B-lymphocyte homeostasis and BLyS-directed immunotherapy in transplantation.

Authors:  Ronald F Parsons; Kumar Vivek; Robert R Redfield; Thi-Sau Migone; Michael P Cancro; Ali Naji; Hooman Noorchashm
Journal:  Transplant Rev (Orlando)       Date:  2010-07-23       Impact factor: 3.943

3.  Management of ANCA-associated vasculitis: Current trends and future prospects.

Authors:  Sally Hamour; Alan D Salama; Charles D Pusey
Journal:  Ther Clin Risk Manag       Date:  2010-06-24       Impact factor: 2.423

Review 4.  Monoclonal Antibodies for Systemic Lupus Erythematosus (SLE).

Authors:  Claudio Ponticelli; Gabriella Moroni
Journal:  Pharmaceuticals (Basel)       Date:  2010-01-20
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.